Specialists in the Pharmaceutical deal-making scope met virtually for the 2020 BIO International Convention last week to discuss the topic of ‘How to Get Acquired: What Companies Look for When in Acquisition Mode,’ including how Covid-19 has radically changed how companies function, with insight on innovative Biotechs looking to be procured by Big Pharma.

The panellists agreed that pre-Covid-19, Big Pharma preferred to acquire an asset pre-launch. Read more here.